aluates Reports

$ 0.0

Automative

Global Targeted Drugs for Breast Cancer Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-17F6058

Global Targeted Drugs for Breast Cancer Market Insights and Forecast to 2028

BUY CHAPTERS

Global Targeted Drugs for Breast Cancer Market Research Report 2024

Code: QYRE-Auto-17F6058

Report

May 2024

Pages:107

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Targeted Drugs for Breast Cancer Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Targeted Drugs for Breast Cancer Market

The global Targeted Drugs for Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Breast Cancer.

Report Scope

The Targeted Drugs for Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Targeted Drugs for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Targeted Drugs for Breast Cancer Market Report

Report Metric	Details
Report Name	Targeted Drugs for Breast Cancer Market
CAGR	5%
Segment by Type	HER-2 Targeted Drugs CDK4/6 Inhibitors PARP Targeted Drugs PI3K/AKT/mTor Pathway Inhibitors ER Targeted Drugs Aromatase Inhibitors Tubulin Inhibitors VEGF Targeted Drugs YTMS Targeted Drugs Others
Segment by Application	Hospital Clinic Drug Center Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group, Hetero, Pfizer, Eli Lilly, Novartis, CANbridge, Puma Biotechnology, AstraZeneca, Chugai Pharmaceutical, Eisai, GlaxoSmithKline, Bristol-Myers Squibb, Otsuka Pharmaceutical, Merck, BioMarin, Hengrui Pharmaceutical, Beijing Biostar Technologies, Bayer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for Breast Cancer Market report?

Ans: The main players in the Targeted Drugs for Breast Cancer Market are Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group, Hetero, Pfizer, Eli Lilly, Novartis, CANbridge, Puma Biotechnology, AstraZeneca, Chugai Pharmaceutical, Eisai, GlaxoSmithKline, Bristol-Myers Squibb, Otsuka Pharmaceutical, Merck, BioMarin, Hengrui Pharmaceutical, Beijing Biostar Technologies, Bayer

What are the Application segmentation covered in the Targeted Drugs for Breast Cancer Market report?

Ans: The Applications covered in the Targeted Drugs for Breast Cancer Market report are Hospital, Clinic, Drug Center, Others

What are the Type segmentation covered in the Targeted Drugs for Breast Cancer Market report?

Ans: The Types covered in the Targeted Drugs for Breast Cancer Market report are HER-2 Targeted Drugs, CDK4/6 Inhibitors, PARP Targeted Drugs, PI3K/AKT/mTor Pathway Inhibitors, ER Targeted Drugs, Aromatase Inhibitors, Tubulin Inhibitors, VEGF Targeted Drugs, YTMS Targeted Drugs, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 HER-2 Targeted Drugs

1.2.3 CDK4/6 Inhibitors

1.2.4 PARP Targeted Drugs

1.2.5 PI3K/AKT/mTor Pathway Inhibitors

1.2.6 ER Targeted Drugs

1.2.7 Aromatase Inhibitors

1.2.8 Tubulin Inhibitors

1.2.9 VEGF Targeted Drugs

1.2.10 YTMS Targeted Drugs

1.2.11 Others

1.3 Market by Application

1.3.1 Global Targeted Drugs for Breast Cancer Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Drug Center

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Targeted Drugs for Breast Cancer Market Perspective (2019-2030)

2.2 Targeted Drugs for Breast Cancer Growth Trends by Region

2.2.1 Global Targeted Drugs for Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2019-2024)

2.2.3 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2025-2030)

2.3 Targeted Drugs for Breast Cancer Market Dynamics

2.3.1 Targeted Drugs for Breast Cancer Industry Trends

2.3.2 Targeted Drugs for Breast Cancer Market Drivers

2.3.3 Targeted Drugs for Breast Cancer Market Challenges

2.3.4 Targeted Drugs for Breast Cancer Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue

3.1.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue (2019-2024)

3.1.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Players (2019-2024)

3.2 Global Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Targeted Drugs for Breast Cancer Revenue

3.4 Global Targeted Drugs for Breast Cancer Market Concentration Ratio

3.4.1 Global Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Breast Cancer Revenue in 2023

3.5 Targeted Drugs for Breast Cancer Key Players Head office and Area Served

3.6 Key Players Targeted Drugs for Breast Cancer Product Solution and Service

3.7 Date of Enter into Targeted Drugs for Breast Cancer Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drugs for Breast Cancer Breakdown Data by Type

4.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Type (2019-2024)

4.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2025-2030)

5 Targeted Drugs for Breast Cancer Breakdown Data by Application

5.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Application (2019-2024)

5.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Targeted Drugs for Breast Cancer Market Size (2019-2030)

6.2 North America Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)

6.4 North America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Targeted Drugs for Breast Cancer Market Size (2019-2030)

7.2 Europe Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)

7.4 Europe Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size (2019-2030)

8.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2019-2024)

8.4 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Targeted Drugs for Breast Cancer Market Size (2019-2030)

9.2 Latin America Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)

9.4 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size (2019-2030)

10.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)

10.4 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Detail

11.1.2 Roche Business Overview

11.1.3 Roche Targeted Drugs for Breast Cancer Introduction

11.1.4 Roche Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.1.5 Roche Recent Development

11.2 Teva

11.2.1 Teva Company Detail

11.2.2 Teva Business Overview

11.2.3 Teva Targeted Drugs for Breast Cancer Introduction

11.2.4 Teva Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.2.5 Teva Recent Development

11.3 Mylan

11.3.1 Mylan Company Detail

11.3.2 Mylan Business Overview

11.3.3 Mylan Targeted Drugs for Breast Cancer Introduction

11.3.4 Mylan Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.3.5 Mylan Recent Development

11.4 Hikma

11.4.1 Hikma Company Detail

11.4.2 Hikma Business Overview

11.4.3 Hikma Targeted Drugs for Breast Cancer Introduction

11.4.4 Hikma Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.4.5 Hikma Recent Development

11.5 Hengrui Medicine

11.5.1 Hengrui Medicine Company Detail

11.5.2 Hengrui Medicine Business Overview

11.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Introduction

11.5.4 Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.5.5 Hengrui Medicine Recent Development

11.6 Cipla

11.6.1 Cipla Company Detail

11.6.2 Cipla Business Overview

11.6.3 Cipla Targeted Drugs for Breast Cancer Introduction

11.6.4 Cipla Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.6.5 Cipla Recent Development

11.7 Reliance Group

11.7.1 Reliance Group Company Detail

11.7.2 Reliance Group Business Overview

11.7.3 Reliance Group Targeted Drugs for Breast Cancer Introduction

11.7.4 Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.7.5 Reliance Group Recent Development

11.8 Hetero

11.8.1 Hetero Company Detail

11.8.2 Hetero Business Overview

11.8.3 Hetero Targeted Drugs for Breast Cancer Introduction

11.8.4 Hetero Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.8.5 Hetero Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Detail

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Targeted Drugs for Breast Cancer Introduction

11.9.4 Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.9.5 Pfizer Recent Development

11.10 Eli Lilly

11.10.1 Eli Lilly Company Detail

11.10.2 Eli Lilly Business Overview

11.10.3 Eli Lilly Targeted Drugs for Breast Cancer Introduction

11.10.4 Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.10.5 Eli Lilly Recent Development

11.11 Novartis

11.11.1 Novartis Company Detail

11.11.2 Novartis Business Overview

11.11.3 Novartis Targeted Drugs for Breast Cancer Introduction

11.11.4 Novartis Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.11.5 Novartis Recent Development

11.12 CANbridge

11.12.1 CANbridge Company Detail

11.12.2 CANbridge Business Overview

11.12.3 CANbridge Targeted Drugs for Breast Cancer Introduction

11.12.4 CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.12.5 CANbridge Recent Development

11.13 Puma Biotechnology

11.13.1 Puma Biotechnology Company Detail

11.13.2 Puma Biotechnology Business Overview

11.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Introduction

11.13.4 Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.13.5 Puma Biotechnology Recent Development

11.14 AstraZeneca

11.14.1 AstraZeneca Company Detail

11.14.2 AstraZeneca Business Overview

11.14.3 AstraZeneca Targeted Drugs for Breast Cancer Introduction

11.14.4 AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.14.5 AstraZeneca Recent Development

11.15 Chugai Pharmaceutical

11.15.1 Chugai Pharmaceutical Company Detail

11.15.2 Chugai Pharmaceutical Business Overview

11.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Introduction

11.15.4 Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.15.5 Chugai Pharmaceutical Recent Development

11.16 Eisai

11.16.1 Eisai Company Detail

11.16.2 Eisai Business Overview

11.16.3 Eisai Targeted Drugs for Breast Cancer Introduction

11.16.4 Eisai Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.16.5 Eisai Recent Development

11.17 GlaxoSmithKline

11.17.1 GlaxoSmithKline Company Detail

11.17.2 GlaxoSmithKline Business Overview

11.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Introduction

11.17.4 GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.17.5 GlaxoSmithKline Recent Development

11.18 Bristol-Myers Squibb

11.18.1 Bristol-Myers Squibb Company Detail

11.18.2 Bristol-Myers Squibb Business Overview

11.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Introduction

11.18.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.18.5 Bristol-Myers Squibb Recent Development

11.19 Otsuka Pharmaceutical

11.19.1 Otsuka Pharmaceutical Company Detail

11.19.2 Otsuka Pharmaceutical Business Overview

11.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Introduction

11.19.4 Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.19.5 Otsuka Pharmaceutical Recent Development

11.20 Merck

11.20.1 Merck Company Detail

11.20.2 Merck Business Overview

11.20.3 Merck Targeted Drugs for Breast Cancer Introduction

11.20.4 Merck Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.20.5 Merck Recent Development

11.21 BioMarin

11.21.1 BioMarin Company Detail

11.21.2 BioMarin Business Overview

11.21.3 BioMarin Targeted Drugs for Breast Cancer Introduction

11.21.4 BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.21.5 BioMarin Recent Development

11.22 Hengrui Pharmaceutical

11.22.1 Hengrui Pharmaceutical Company Detail

11.22.2 Hengrui Pharmaceutical Business Overview

11.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Introduction

11.22.4 Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.22.5 Hengrui Pharmaceutical Recent Development

11.23 Beijing Biostar Technologies

11.23.1 Beijing Biostar Technologies Company Detail

11.23.2 Beijing Biostar Technologies Business Overview

11.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Introduction

11.23.4 Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.23.5 Beijing Biostar Technologies Recent Development

11.24 Bayer

11.24.1 Bayer Company Detail

11.24.2 Bayer Business Overview

11.24.3 Bayer Targeted Drugs for Breast Cancer Introduction

11.24.4 Bayer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)

11.24.5 Bayer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of HER-2 Targeted Drugs

Table 3. Key Players of CDK4/6 Inhibitors

Table 4. Key Players of PARP Targeted Drugs

Table 5. Key Players of PI3K/AKT/mTor Pathway Inhibitors

Table 6. Key Players of ER Targeted Drugs

Table 7. Key Players of Aromatase Inhibitors

Table 8. Key Players of Tubulin Inhibitors

Table 9. Key Players of VEGF Targeted Drugs

Table 10. Key Players of YTMS Targeted Drugs

Table 11. Key Players of Others

Table 12. Global Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 13. Global Targeted Drugs for Breast Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 14. Global Targeted Drugs for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)

Table 15. Global Targeted Drugs for Breast Cancer Market Share by Region (2019-2024)

Table 16. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 17. Global Targeted Drugs for Breast Cancer Market Share by Region (2025-2030)

Table 18. Targeted Drugs for Breast Cancer Market Trends

Table 19. Targeted Drugs for Breast Cancer Market Drivers

Table 20. Targeted Drugs for Breast Cancer Market Challenges

Table 21. Targeted Drugs for Breast Cancer Market Restraints

Table 22. Global Targeted Drugs for Breast Cancer Revenue by Players (2019-2024) & (US$ Million)

Table 23. Global Targeted Drugs for Breast Cancer Market Share by Players (2019-2024)

Table 24. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Breast Cancer as of 2023)

Table 25. Ranking of Global Top Targeted Drugs for Breast Cancer Companies by Revenue (US$ Million) in 2023

Table 26. Global 5 Largest Players Market Share by Targeted Drugs for Breast Cancer Revenue (CR5 and HHI) & (2019-2024)

Table 27. Key Players Headquarters and Area Served

Table 28. Key Players Targeted Drugs for Breast Cancer Product Solution and Service

Table 29. Date of Enter into Targeted Drugs for Breast Cancer Market

Table 30. Mergers & Acquisitions, Expansion Plans

Table 31. Global Targeted Drugs for Breast Cancer Market Size by Type (2019-2024) & (US$ Million)

Table 32. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2019-2024)

Table 33. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 34. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2025-2030)

Table 35. Global Targeted Drugs for Breast Cancer Market Size by Application (2019-2024) & (US$ Million)

Table 36. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2019-2024)

Table 37. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 38. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2025-2030)

Table 39. North America Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. North America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 41. North America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 42. Europe Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Europe Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 44. Europe Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 45. Asia-Pacific Targeted Drugs for Breast Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 46. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)

Table 47. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2025-2030) & (US$ Million)

Table 48. Latin America Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 49. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 50. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 51. Middle East & Africa Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 52. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)

Table 53. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)

Table 54. Roche Company Detail

Table 55. Roche Business Overview

Table 56. Roche Targeted Drugs for Breast Cancer Product

Table 57. Roche Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 58. Roche Recent Development

Table 59. Teva Company Detail

Table 60. Teva Business Overview

Table 61. Teva Targeted Drugs for Breast Cancer Product

Table 62. Teva Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 63. Teva Recent Development

Table 64. Mylan Company Detail

Table 65. Mylan Business Overview

Table 66. Mylan Targeted Drugs for Breast Cancer Product

Table 67. Mylan Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 68. Mylan Recent Development

Table 69. Hikma Company Detail

Table 70. Hikma Business Overview

Table 71. Hikma Targeted Drugs for Breast Cancer Product

Table 72. Hikma Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 73. Hikma Recent Development

Table 74. Hengrui Medicine Company Detail

Table 75. Hengrui Medicine Business Overview

Table 76. Hengrui Medicine Targeted Drugs for Breast Cancer Product

Table 77. Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 78. Hengrui Medicine Recent Development

Table 79. Cipla Company Detail

Table 80. Cipla Business Overview

Table 81. Cipla Targeted Drugs for Breast Cancer Product

Table 82. Cipla Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 83. Cipla Recent Development

Table 84. Reliance Group Company Detail

Table 85. Reliance Group Business Overview

Table 86. Reliance Group Targeted Drugs for Breast Cancer Product

Table 87. Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 88. Reliance Group Recent Development

Table 89. Hetero Company Detail

Table 90. Hetero Business Overview

Table 91. Hetero Targeted Drugs for Breast Cancer Product

Table 92. Hetero Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 93. Hetero Recent Development

Table 94. Pfizer Company Detail

Table 95. Pfizer Business Overview

Table 96. Pfizer Targeted Drugs for Breast Cancer Product

Table 97. Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 98. Pfizer Recent Development

Table 99. Eli Lilly Company Detail

Table 100. Eli Lilly Business Overview

Table 101. Eli Lilly Targeted Drugs for Breast Cancer Product

Table 102. Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 103. Eli Lilly Recent Development

Table 104. Novartis Company Detail

Table 105. Novartis Business Overview

Table 106. Novartis Targeted Drugs for Breast Cancer Product

Table 107. Novartis Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 108. Novartis Recent Development

Table 109. CANbridge Company Detail

Table 110. CANbridge Business Overview

Table 111. CANbridge Targeted Drugs for Breast Cancer Product

Table 112. CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 113. CANbridge Recent Development

Table 114. Puma Biotechnology Company Detail

Table 115. Puma Biotechnology Business Overview

Table 116. Puma Biotechnology Targeted Drugs for Breast Cancer Product

Table 117. Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 118. Puma Biotechnology Recent Development

Table 119. AstraZeneca Company Detail

Table 120. AstraZeneca Business Overview

Table 121. AstraZeneca Targeted Drugs for Breast Cancer Product

Table 122. AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 123. AstraZeneca Recent Development

Table 124. Chugai Pharmaceutical Company Detail

Table 125. Chugai Pharmaceutical Business Overview

Table 126. Chugai Pharmaceutical Targeted Drugs for Breast Cancer Product

Table 127. Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 128. Chugai Pharmaceutical Recent Development

Table 129. Eisai Company Detail

Table 130. Eisai Business Overview

Table 131. Eisai Targeted Drugs for Breast Cancer Product

Table 132. Eisai Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 133. Eisai Recent Development

Table 134. GlaxoSmithKline Company Detail

Table 135. GlaxoSmithKline Business Overview

Table 136. GlaxoSmithKline Targeted Drugs for Breast Cancer Product

Table 137. GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 138. GlaxoSmithKline Recent Development

Table 139. Bristol-Myers Squibb Company Detail

Table 140. Bristol-Myers Squibb Business Overview

Table 141. Bristol-Myers Squibb Targeted Drugs for Breast Cancer Product

Table 142. Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 143. Bristol-Myers Squibb Recent Development

Table 144. Otsuka Pharmaceutical Company Detail

Table 145. Otsuka Pharmaceutical Business Overview

Table 146. Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Product

Table 147. Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 148. Otsuka Pharmaceutical Recent Development

Table 149. Merck Company Detail

Table 150. Merck Business Overview

Table 151. Merck Targeted Drugs for Breast Cancer Product

Table 152. Merck Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 153. Merck Recent Development

Table 154. BioMarin Company Detail

Table 155. BioMarin Business Overview

Table 156. BioMarin Targeted Drugs for Breast Cancer Product

Table 157. BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 158. BioMarin Recent Development

Table 159. Hengrui Pharmaceutical Company Detail

Table 160. Hengrui Pharmaceutical Business Overview

Table 161. Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Product

Table 162. Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 163. Hengrui Pharmaceutical Recent Development

Table 164. Beijing Biostar Technologies Company Detail

Table 165. Beijing Biostar Technologies Business Overview

Table 166. Beijing Biostar Technologies Targeted Drugs for Breast Cancer Product

Table 167. Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 168. Beijing Biostar Technologies Recent Development

Table 169. Bayer Company Detail

Table 170. Bayer Business Overview

Table 171. Bayer Targeted Drugs for Breast Cancer Product

Table 172. Bayer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)

Table 173. Bayer Recent Development

Table 174. Research Programs/Design for This Report

Table 175. Key Data Information from Secondary Sources

Table 176. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Targeted Drugs for Breast Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Targeted Drugs for Breast Cancer Market Share by Type: 2023 VS 2030

Figure 3. HER-2 Targeted Drugs Features

Figure 4. CDK4/6 Inhibitors Features

Figure 5. PARP Targeted Drugs Features

Figure 6. PI3K/AKT/mTor Pathway Inhibitors Features

Figure 7. ER Targeted Drugs Features

Figure 8. Aromatase Inhibitors Features

Figure 9. Tubulin Inhibitors Features

Figure 10. VEGF Targeted Drugs Features

Figure 11. YTMS Targeted Drugs Features

Figure 12. Others Features

Figure 13. Global Targeted Drugs for Breast Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 14. Global Targeted Drugs for Breast Cancer Market Share by Application: 2023 VS 2030

Figure 15. Hospital Case Studies

Figure 16. Clinic Case Studies

Figure 17. Drug Center Case Studies

Figure 18. Others Case Studies

Figure 19. Targeted Drugs for Breast Cancer Report Years Considered

Figure 20. Global Targeted Drugs for Breast Cancer Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 21. Global Targeted Drugs for Breast Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 22. Global Targeted Drugs for Breast Cancer Market Share by Region: 2023 VS 2030

Figure 23. Global Targeted Drugs for Breast Cancer Market Share by Players in 2023

Figure 24. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Breast Cancer as of 2023)

Figure 25. The Top 10 and 5 Players Market Share by Targeted Drugs for Breast Cancer Revenue in 2023

Figure 26. North America Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. North America Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)

Figure 28. United States Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Canada Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Europe Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Europe Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)

Figure 32. Germany Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. France Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. U.K. Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Italy Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Russia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Nordic Countries Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Asia-Pacific Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Asia-Pacific Targeted Drugs for Breast Cancer Market Share by Region (2019-2030)

Figure 40. China Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Japan Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. South Korea Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. India Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Australia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Latin America Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Latin America Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)

Figure 48. Mexico Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Brazil Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Middle East & Africa Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)

Figure 52. Turkey Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Roche Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 55. Teva Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 56. Mylan Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 57. Hikma Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 58. Hengrui Medicine Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 59. Cipla Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 60. Reliance Group Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 61. Hetero Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 62. Pfizer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 63. Eli Lilly Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 64. Novartis Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 65. CANbridge Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 66. Puma Biotechnology Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 67. AstraZeneca Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 68. Chugai Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 69. Eisai Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 70. GlaxoSmithKline Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 71. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 72. Otsuka Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 73. Merck Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 74. BioMarin Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 75. Hengrui Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 76. Beijing Biostar Technologies Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 77. Bayer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)

Figure 78. Bottom-up and Top-down Approaches for This Report

Figure 79. Data Triangulation

Figure 80. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global VEGF Targeted Drugs for Breast Cancer Market Research Report 2024

Global HER 2 Targeted Drugs for Breast Cancer Market Research Report 2024

Breast Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Endocrine Therapy Drugs for Breast Cancer Market Research Report 2024

Global Targeted Drugs for NSCLC Market Research Report 2024

Breast Cancer Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gynecological Cancers Drug Market Research Report 2025

Global Personalized Medicine for Cancer Market Research Report 2025

Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drug HER2 Inhibitors for NSCLC Market Research Report 2024

Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024

Global Small Molecule Cancer Drug Market Research Report 2025

Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancers Immunotherapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Personalizing Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kidney Cancer Diagnosis Market Research Report 2025

Precision Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Targeted Drugs for Breast Cancer Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-17F6058

Global Targeted Drugs for Breast Cancer Market Research Report 2024

FEATURED COMPANIES

Targeted Drugs for Breast Cancer Market Size

Targeted Drugs for Breast Cancer Market

Report Scope

Scope of Targeted Drugs for Breast Cancer Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Targeted Drugs for Breast Cancer Market report?

What are the Application segmentation covered in the Targeted Drugs for Breast Cancer Market report?

What are the Type segmentation covered in the Targeted Drugs for Breast Cancer Market report?

FEATURED COMPANIES